36: Progression-Free Survival and Local Control Following Stereotactic Ablative Radiotherapy for Up to Five Oligometastases: An Analysis from the Population-Based Phase II SABR-5 Trial. (September 2022) - Baker, Sarah; Jiang, Will (Wei Ning); Mou, Benjamin; Lund, Chad; Liu, Mitchell; Bergman, Alanah; Schellenberg, Devin; Alexander, Abraham; Carolan, Hannah; Atrchian, Siavash; Chng, Nick; Matthews, Quinn; et al.